Summary
Danaher Corporation's Q3 2024 Form 10-Q filing indicates a mixed performance across its segments, with overall revenues seeing a 3.0% increase year-over-year, driven by acquisitions and price increases, while core sales grew by a modest 0.5%. The Diagnostics segment was a key performer, demonstrating strong core sales growth. However, the Life Sciences and Biotechnology segments experienced core sales declines, with Life Sciences impacted by an impairment charge and increased acquisition dilution, and Biotechnology facing reduced demand and inventory rationalization from larger customers. Net earnings from continuing operations saw a year-over-year decline, impacted by intangible asset impairments and increased operating expenses. The company generated substantial operating cash flow, though it decreased compared to the prior year, largely due to lower net earnings and changes in working capital. Significant cash outflow was observed in financing activities, primarily driven by substantial share repurchases, alongside debt repayments. Danaher maintains a strong liquidity position with significant cash on hand, and expects its effective tax rate for the remainder of 2024 to be around 17.5%.
Financial Highlights
50 data points| Revenue | $5.80B |
| Cost of Revenue | $2.40B |
| Gross Profit | $3.40B |
| R&D Expenses | $383.00M |
| SG&A Expenses | $2.06B |
| Operating Income | $958.00M |
| Net Income | $818.00M |
| EPS (Basic) | $1.13 |
| EPS (Diluted) | $1.12 |
| Shares Outstanding (Basic) | 723.00M |
| Shares Outstanding (Diluted) | 729.40M |
Key Highlights
- 1Overall revenue increased by 3.0% year-over-year in Q3 2024, with core sales growing by 0.5%.
- 2The Diagnostics segment showed robust performance with 5.0% core sales growth in both Q3 and the nine-month period.
- 3Life Sciences and Biotechnology segments experienced core sales declines of 2.0% and flat/declining core sales (Q3/nine-month) respectively, impacted by demand weakness and inventory adjustments.
- 4Q3 2024 net earnings from continuing operations were $818 million, down from $940 million in Q3 2023, primarily due to intangible asset impairments and higher operating expenses.
- 5The company repurchased approximately $5.2 billion of its common stock in the nine-month period ended September 27, 2024, significantly impacting financing cash flows.
- 6Operating cash flow from continuing operations for the first nine months of 2024 was $4.7 billion, a 5% decrease from the prior year, influenced by lower net earnings and working capital changes.
- 7A significant impairment charge of $222 million related to a trade name in the Life Sciences segment negatively impacted operating profit margins.
- 8Danaher ended the period with approximately $2.6 billion in cash and cash equivalents, maintaining a strong liquidity position.